Search

Your search keyword '"Cystic fibrosis"' showing total 3,871 results

Search Constraints

Start Over You searched for: Descriptor "Cystic fibrosis" Remove constraint Descriptor: "Cystic fibrosis" Publication Type Magazines Remove constraint Publication Type: Magazines
3,871 results on '"Cystic fibrosis"'

Search Results

1. Term Dependence: Truncating the Bahadur Lazarsfeld Expansion.

2. Chronic Illness in Adolescents: A Sociological Perspective.

3. Royalty Pharma price target lowered by $20 at Citi, here's why

4. Vertex Pharmaceuticals price target raised by $85 at UBS, here's why

5. Vertex Pharmaceuticals initiated with neutral view at Scotiabank, here's why

6. Vertex Pharmaceuticals price target lowered by $9 at BofA, here's why

7. Vertex Pharmaceuticals resumed with a Market Perform at Raymond James

8. Insmed price target raised by $2 at BofA, here's why

10. Sophie Grace Holmes

13. Claire's Place Foundation to Host 10th Annual Glow Ride for Cystic Fibrosis

15. Is Vertex Pharmaceuticals Stock Outperforming the Nasdaq?

16. Nutrition Interventions for Pancreatic Insufficiency.

19. Royalty Pharma reports Q2 revenue $537M, consensus $628.52M

20. Vertex Pharmaceuticals just downgraded at Barclays, here's why

21. Vertex Pharmaceuticals price target raised by $50 at Oppenheimer, here's why

23. Research and Marketa Brings Out Report: Cystic Fibrosis Therapeutics Market 2024-2032

24. Vertex Pharmaceuticals price target raised by $53 at Morgan Stanley, here's why

25. Armata Pharmaceuticals completes enrollment of Phase 2 study of AP-PA02

26. Scientists map how deadly bacteria evolved to become epidemic

27. Arcturus Therapeutics updates on OTC deficiency in CF programs

28. Insmed price target raised by $17 at JPMorgan, here's why

29. Vertex Pharmaceuticals price target raised by $85 at Argus, here's why

30. Vertex Pharmaceuticals price target lowered by $3 at RBC Capital, here's why

31. Arcturus Therapeutics weakness after CF data 'overblown,' says William Blair

32. Vertex Pharmaceuticals presents new data at ECFS on TRIKAFTA treatment

33. 4D Molecular presents interim data from Phase 1/2 AEROW trial

35. CRISPR lung treatment offers hope for cystic fibrosis.

37. Krystal Biotech to present preclinical data on KB407, KB408

38. Vertex announces European Commission approval for KALYDECO

39. 4D Molecular price target raised by $5 at RBC Capital, here's why

40. 4D Molecular assumed with a Buy at Jefferies

42. Data on Pseudomonas aeruginosa Described by Researchers at East Carolina University (Advances in Development of Novel Therapeutic Strategies against Multi-Drug Resistant * * Pseudomonas aeruginosa* *)

43. Krankenversicherung: Einschließlich Pflegeversicherung und Beitragsrecht der Kranken-, Renten- und Arbeitslosenversicherung.

44. EC grants orphan medicinal product designation to Arcturus Therapeutics' ARCT-032 to treat cystic fibrosis

46. Studies from University of Iowa Describe New Findings in Science (Shuttle peptide delivers base editor RNPs to rhesus monkey airway epithelial cells in vivo)

47. Vertex: EMA Validates Marketing Authorization Application Extension for KAFTRIO in Combination with Ivacaftor

48. Researchers' Work from University of Rouen Normandy Focuses on Pseudomonas aeruginosa (High Affinity Iron Uptake By Pyoverdine In pseudomonas Aeruginosa Involves Multiple Regulators Besides Fur, Pvds, and Fpvi)

Catalog

Books, media, physical & digital resources